Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Sanofi has been given a reprimand by the UK's Prescription Medicines Code of Practice Authority (PMCPA), after admitting that ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Giusy Di Conza, head of research at small molecule cancer therapeutics firm iOnctura, said ADCs were “heralding a shift ...

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...